CA3068588A1 - Methods of treating heart failure with cardiac sarcomere activators - Google Patents

Methods of treating heart failure with cardiac sarcomere activators Download PDF

Info

Publication number
CA3068588A1
CA3068588A1 CA3068588A CA3068588A CA3068588A1 CA 3068588 A1 CA3068588 A1 CA 3068588A1 CA 3068588 A CA3068588 A CA 3068588A CA 3068588 A CA3068588 A CA 3068588A CA 3068588 A1 CA3068588 A1 CA 3068588A1
Authority
CA
Canada
Prior art keywords
subject
dose
csa
time period
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3068588A
Other languages
English (en)
French (fr)
Inventor
Narimon HONARPOUR
Fady Malik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Cytokinetics Inc
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Publication of CA3068588A1 publication Critical patent/CA3068588A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3068588A 2017-06-30 2018-06-29 Methods of treating heart failure with cardiac sarcomere activators Pending CA3068588A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
US62/527,983 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Publications (1)

Publication Number Publication Date
CA3068588A1 true CA3068588A1 (en) 2019-01-03

Family

ID=63013097

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3068588A Pending CA3068588A1 (en) 2017-06-30 2018-06-29 Methods of treating heart failure with cardiac sarcomere activators

Country Status (22)

Country Link
US (4) US11576910B2 (https=)
EP (2) EP3645002B1 (https=)
JP (3) JP2020526483A (https=)
CN (1) CN110996953A (https=)
AU (2) AU2018290983B2 (https=)
BR (1) BR112019028046A2 (https=)
CA (1) CA3068588A1 (https=)
DK (1) DK3645002T3 (https=)
ES (1) ES3008457T3 (https=)
FI (1) FI3645002T3 (https=)
HR (1) HRP20241729T1 (https=)
HU (1) HUE069805T2 (https=)
LT (1) LT3645002T (https=)
MA (1) MA49508B1 (https=)
MD (1) MD3645002T2 (https=)
MX (2) MX2020000190A (https=)
PL (1) PL3645002T3 (https=)
PT (1) PT3645002T (https=)
RS (1) RS66581B1 (https=)
SI (1) SI3645002T1 (https=)
SM (1) SMT202500067T1 (https=)
WO (1) WO2019006235A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
DK3645002T3 (da) * 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
KR20220009440A (ko) * 2019-05-19 2022-01-24 미요카디아, 인크. 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료
US20230090391A1 (en) * 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
WO2021257456A1 (en) * 2020-06-15 2021-12-23 MyoKardia, Inc. Treatment of atrial dysfunction
DK4243825T3 (da) * 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
US20250161298A1 (en) * 2022-02-22 2025-05-22 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
JP2025534288A (ja) 2022-09-26 2025-10-15 エッジワイズ セラピューティクス， インコーポレイテッド １，４－ジヒドロキナゾリノン化合物およびその使用
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
AU2003279842A1 (en) 2002-10-04 2004-05-04 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US20080031957A1 (en) 2006-05-15 2008-02-07 Deluca Hector F Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
US9895308B2 (en) * 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
CA3052625A1 (en) 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
DK3645002T3 (da) 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
EP3820851A1 (en) 2018-07-12 2021-05-19 Assia Chemical Industries Ltd Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
FI3599243T3 (fi) 2018-07-26 2023-06-22 Cvie Therapeutics Ltd 17beeta-heterosyklyylidigitaliksen kaltaisia yhdisteitä sydämen vajaatoiminnan hoitoon
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
MX2021010483A (es) 2019-03-05 2021-10-01 Windtree Therapeutics Inc Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf).
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
EP4054588A4 (en) 2019-11-10 2023-12-13 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
US20230090391A1 (en) 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
DK4243825T3 (da) 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
EP4512470A3 (en) 2025-04-23
US11576910B2 (en) 2023-02-14
HUE069805T2 (hu) 2025-04-28
MX2020000190A (es) 2020-07-22
EP3645002A1 (en) 2020-05-06
SMT202500067T1 (it) 2025-03-12
EP3645002B1 (en) 2024-10-30
US20250255862A1 (en) 2025-08-14
US20200155547A1 (en) 2020-05-21
AU2024200991B2 (en) 2025-04-10
AU2024200991A1 (en) 2024-03-07
US11931358B2 (en) 2024-03-19
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07
RS66581B1 (sr) 2025-04-30
MA49508A (fr) 2020-05-06
PT3645002T (pt) 2025-01-24
AU2018290983B2 (en) 2023-11-23
WO2019006235A1 (en) 2019-01-03
MA49508B1 (fr) 2024-12-31
HRP20241729T1 (hr) 2025-03-14
MX2022015115A (es) 2023-01-18
PL3645002T3 (pl) 2025-03-24
JP2025165979A (ja) 2025-11-05
FI3645002T3 (fi) 2025-01-29
JP2020526483A (ja) 2020-08-31
MD3645002T2 (ro) 2025-04-30
DK3645002T3 (da) 2024-12-16
ES3008457T3 (en) 2025-03-24
CN110996953A (zh) 2020-04-10
US12295952B2 (en) 2025-05-13
EP4512470A2 (en) 2025-02-26
LT3645002T (lt) 2025-02-10
SI3645002T1 (sl) 2025-03-31
JP2023088944A (ja) 2023-06-27
US20230149394A1 (en) 2023-05-18
US20230355615A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
AU2024200991B2 (en) Methods of treating heart failure with cardiac sarcomere activators
Sayin et al. Left ventricular hypertrophy: etiology-based therapeutic options
US12194039B2 (en) Methods of treating heart failure by administering omecamtiv mecarbil
Von Lueder et al. New medical therapies for heart failure
US20200069644A1 (en) Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure
KR20250050043A (ko) 비폐쇄성 비대심근병증 치료 방법
Yuyun et al. Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review
Murdoch et al. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects
Bernier et al. Cardiac myosin activation for the treatment of systolic heart failure
Cada et al. Sacubitril/valsartan
US20260041679A1 (en) Method of treating hypertension with the aldosterone synthase inhibitor baxdrostat
KR20250056200A (ko) 폐쇄성 비대심장근육병증 치료 방법
HK40028258A (en) Methods of treating heart failure with cardiac sarcomere activators
HK40028258B (en) Methods of treating heart failure with cardiac sarcomere activators
HK40027649A (en) Methods of treating heart failure with cardiac sarcomere activators
Kato et al. Inefficacy of a Highly Selective T‐Type Calcium Channel Blocker in Preventing Atrial Fibrillation Related Remodeling
KR20210032437A (ko) 심부전의 치료를 위한 신규한 약제학적 용도
Ahmed et al. Sacubitril/Valsartan: A Novel Approach in the Treatment of Heart Failure with Reduced Ejection Fraction
Hamdy et al. Why Pillar Directed Therapy Does Not Provide Absolute Protection in Heart Failure? The Five Pillars of the Management of Heart Failure
Sabharwal et al. Effect of imidapril and nifedipine on left ventricular hypertrophy in untreated hypertension
Oto Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options
WO2012013750A1 (en) Use of dronedarone for the preparation of a medicament for the hospitalization burden in patient with atrial fibrillation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220909

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250530

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250606

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250606

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250919

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251126

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251126